title: [Corneal herpes: what's new?].
abstract: The prognosis of herpetic keratitis has been dramatically improved during the past years because of a better understanding of their physio-pathologic phenomenons, and mostly because of the use of very efficient antiviral drugs. Superficial keratitis are easily cured in most cases; deep stromal keratitis, that often require corticosteroid treatment, are more difficult to heal. Prophylactic treatment of the recurrences by oral antiviral drugs represents a promising new concept for herpetic keratitis.
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D016039:Corneal Transplantation; D009877:Endophthalmitis / Q000821:virology; D005602:France / Q000453:epidemiology; D006801:Humans; D016849:Keratitis, Herpetic / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D015337:Multicenter Studies as Topic; D012008:Recurrence; D014481:United States / Q000453:epidemiology
chemical_list: D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents; D000212:Acyclovir
vernacular_title: Herpès cornéen: quoi de neuf?